Fast‐acting insulin aspart versus insulin aspart in the setting of insulin degludec‐treated type 1 diabetes: Efficacy and safety from a randomized double‐blind trial

To evaluate the efficacy and safety of mealtime or post‐meal fast‐acting insulin aspart (faster aspart) vs mealtime insulin aspart (IAsp), both in combination with insulin degludec, in participants with type 1 diabetes (T1D).

• Publication year

  2018

• Venue

  Diabetes, obesity and metabolism

• Publication date

  2018-10-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/dom.13545PMID 30259644PMCID 6231963
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fast-Acting Insulin Aspart: The Rationale for a New Mealtime Insulin

  2019cited by this paper
• Use of fast‐acting insulin aspart in insulin pump therapy in clinical practice

  2019cited by this paper
• The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.

  2019cited by this paper
• Fast‐acting insulin aspart versus insulin aspart in the setting of insulin degludec‐treated type 1 diabetes: Efficacy and safety from a randomized double‐blind trial

  2018cited by this paper
• Efficacy and safety of fast‐acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52‐week, randomized, treat‐to‐target, phase III trial

  2018cited by this paper
• Adding fast‐acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18‐week, open‐label, phase 3 trial (onset 3)

  2017cited by this paper
• Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial

  2017cited by this paper
• 6. Glycemic Targets: Standards of Medical Care in Diabetes—2018

  2017cited by this paper
• A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes

  2017cited by this paper
• Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial

  2017cited by this paper
• Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes

  2017cited by this paper
• Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1)

  2017influential reference
• The beneficial effect of insulin degludec on nocturnal hypoglycaemia and insulin dose in type 1 diabetic patients: a systematic review and meta-analysis of randomised trials

  2015cited by this paper
• The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?

  2014cited by this paper
• Guideline for management of postmeal glucose in diabetes.

  2014cited by this paper
• Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society

  2013cited by this paper
• The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview

  2013cited by this paper
• Undeniable Need for Ultrafast-Acting Insulin: The Pediatric Perspective

  2012cited by this paper
• Insulin Use in Elderly Adults: Risk of Hypoglycemia and Strategies for Care

  2012cited by this paper
• Coverage of Prandial Insulin Requirements by Means of an Ultra-Rapid-Acting Inhaled Insulin

  2012cited by this paper
• Standards of medical care in diabetes.

  2006cited by this paper
• Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

  2005cited by this paper
• Long-term complications of diabetes mellitus.

  1993cited by this paper

• Type 1 Diabetes: A Review.

  2026cites this paper
• Comparison of pharmacodynamics and pharmacokinetics of ultra-rapid-acting insulin aspart and rapid-acting insulin aspart around continuous moderate intensity exercise in adults with type 1 diabetes: A randomised controlled trial.

  2026cites this paper
• Faster‐acting insulin aspart versus insulin aspart for adults with type 1 diabetes treated with non‐automated insulin pump and continuous glucose monitoring—A double‐blind randomized controlled crossover trial

  2025cites this paper
• Insulin Delivery Devices in Diabetes Management: Applications and Advancements

  2025cites this paper
• Ultrafast-acting insulin: pharmacological properties and their impact on clinical aspects

  2024cites this paper
• New advances in type 1 diabetes

  2024influential citation
• Fast-Acting Insulin Aspart in Patients with Type 1 Diabetes in Real-World Clinical Practice: A Noninterventional, Retrospective Chart and Database Study

  2023cites this paper
• [New Insulins for Type 1 Diabetes treatment].

  2023cites this paper
• A gyors aszpart inzulin

  2023cites this paper
• The Role of Ultra-Rapid-Acting Insulin Analogs in Diabetes: An Expert Consensus

  2023influential citation
• Ultrarapid Insulin Use Can Reduce Postprandial Hyperglycemia and Late Hypoglycemia, Even in Delayed Insulin Injections: A Connected Insulin Cap-Based Real-World Study

  2023cites this paper
• Effect of Postmeal Fast-Acting Insulin Aspart Injection on the Frequency of Hypoglycemia among Pre-School Children with Type 1 Diabetes: An Open-Label, Cross-Over, Randomized Control Trial

  2023cites this paper
• Faster-acting insulin aspart versus insulin aspart in the treatment of type 1 or type 2 diabetes during pregnancy and post-delivery (CopenFast): an open-label, single-centre, randomised controlled trial.

  2023cites this paper
• Rapid-Acting Insulin Analogues: Theory and Best Clinical Practice in Type 1 and Type 2 Diabetes.

  2022cites this paper
• Efficacy and Safety of Faster Aspart in Comparison to Insulin Aspart Among Indian Women with Gestational Diabetes.

  2022cites this paper
• The 2021–2022 position of Brazilian Diabetes Society on insulin therapy in type 1 diabetes: an evidence-based guideline to clinical practice

  2022cites this paper
• The Effect of Two Different Insulin Formulations on Postprandial Hyperglycemia after High and Low Glycemic-Index Meal in Type 1 Diabetes

  2022cites this paper
• Can Faster Aspart Be Used to Optimize Glycemic Control With Insulin Pump Therapy? From Expectations to Lessons Learned After a Year of Use in the United States

  2022cites this paper
• One-hundred year evolution of prandial insulin preparations: from animal pancreas extracts to rapid-ACTING analogs.

  2021cites this paper
• Glycaemic efficacy and safety of mealtime faster‐acting insulin aspart administered by injection as compared to insulin aspart in people with diabetes mellitus: A meta‐analysis of randomized controlled trials

  2021cites this paper
• Efficacy and safety of fast-acting insulin aspart versus insulin aspart in children and adolescents with type 1 diabetes from Japan.

  2021cites this paper
• CopenFast trial: Faster-acting insulin Fiasp versus insulin NovoRapid in the treatment of women with type 1 or type 2 diabetes during pregnancy and lactation - a randomised controlled trial

  2021cites this paper
• Ultra‐rapid‐acting insulins for adults with diabetes: A systematic review and meta‐analysis

  2021cites this paper
• Fast-acting insulin aspart - from insulin portraits to patient portraits

  2021cites this paper
• Glucose control using fast‐acting insulin aspart in a real‐world setting: A 1‐year, two‐centre study in people with type 1 diabetes using continuous glucose monitoring

  2021influential citation
• Glycaemic Control in People with Diabetes Starting Treatment with Fast-Acting Insulin Aspart: a US Database Study

  2021cites this paper
• The impact of "faster aspart" on blood glucose control in children and adolescents with type 1 diabetes treated using a sensor-augmented insulin pump.

  2021cites this paper
• Charting the next century of insulin replacement with cell and gene therapies.

  2021cites this paper
• Ultrafast acting insulin analog – a new way to prevent postprandial hyperglycemia and improve quality of life in type 1 diabetes patients – case reports

  2021cites this paper
• Insulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative Review

  2020cites this paper
• Efficacy and safety of fast-acting insulin aspart compared with insulin aspart in combination with insulin degludec in Japanese adults with type 1 diabetes: a subgroup analysis of the randomized onset 8 trial.

  2020influential citation
• [The impact of «faster aspart» on blood glucose control in children and adolescents with type 1 diabetes treated using a sensor-augmented insulin pump].

  2020cites this paper
• Advances in newer basal and bolus insulins: impact on type 1 diabetes.

  2020cites this paper
• Improving the treatment of patients with diabetes using insulin analogues: current findings and future directions

  2020cites this paper
• Contrôle de la glycémie post-prandiale : apport des nouvelles formulations d’insuline ultra-rapides

  2020cites this paper
• Impact of Fast-Acting Insulin Aspart on Glycemic Control in Patients with Type 1 Diabetes Using Intermittent-Scanning Continuous Glucose Monitoring Within a Real-World Setting: The GoBolus Study

  2020cites this paper
• The association between anti‐insulin aspart antibodies and the pharmacokinetic and pharmacodynamic characteristics of fast‐acting insulin aspart in children and adolescents with type 1 diabetes

  2020cites this paper
• A survey of physician experience and treatment satisfaction using fast-acting insulin aspart in people with type 1 or type 2 diabetes

  2020cites this paper
• The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications

  2020influential citation
• Efficacy and Safety of Fast-Acting Insulin Aspart in People with Type 1 Diabetes Using Carbohydrate Counting: A Post Hoc Analysis of Two Randomised Controlled Trials

  2019cites this paper
• Typ-1-Diabetes

  2019cites this paper
• Use of fast‐acting insulin aspart in insulin pump therapy in clinical practice

  2019cites this paper
• Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial

  2019cites this paper
• Fast-Acting Insulin Aspart and the Need for New Mealtime Insulin Analogues in Adults With Type 1 and Type 2 Diabetes: A Canadian Perspective.

  2019cites this paper
• Biosimilars and Novel Insulins.

  2019cites this paper
• Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences

  2019cites this paper
• Fast-Acting Insulin Aspart: The Rationale for a New Mealtime Insulin

  2019cites this paper
• Role of ultrafast-acting insulin analogues in the management of diabetes.

  2019influential citation
• Mealtime fast‐acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin‐resistant Type 2 diabetes

  2018cites this paper
• Fast‐acting insulin aspart versus insulin aspart in the setting of insulin degludec‐treated type 1 diabetes: Efficacy and safety from a randomized double‐blind trial

  2018cites this paper
• Diagnóstico y terapéutica

  2016cites this paper